-
1
-
-
79952721484
-
Advances in the biology and treatment of bone disease in multiple myeloma
-
Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011; 17: 1278-1286.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1278-1286
-
-
Raje, N.1
Roodman, G.D.2
-
2
-
-
0024786736
-
Mechanisms of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone disease
-
Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989; 7: 1909-1914. (Pubitemid 20014340)
-
(1989)
Journal of Clinical Oncology
, vol.7
, Issue.12
, pp. 1909-1914
-
-
Bataille, R.1
Chappard, D.2
Marcelli, C.3
Dessauw, P.4
Sany, J.5
Baldet, P.6
Alexandre, C.7
-
3
-
-
33751193178
-
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition
-
DOI 10.1182/blood-2006-05-026112
-
Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophy-siology of osteoblast inhibition. Blood 2006; 108: 3992-3996. (Pubitemid 44913267)
-
(2006)
Blood
, vol.108
, Issue.13
, pp. 3992-3996
-
-
Giuliani, N.1
Rizzoli, V.2
Roodman, G.D.3
-
4
-
-
47649085380
-
Thalidomide and lenalidomide: Mechanism-based potential drug combinations
-
DOI 10.1080/10428190802005191, PII 792758569
-
Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008; 49: 1238-1245. (Pubitemid 352015786)
-
(2008)
Leukemia and Lymphoma
, vol.49
, Issue.7
, pp. 1238-1245
-
-
Vallet, S.1
Palumbo, A.2
Raje, N.3
Boccadoro, M.4
Anderson, K.C.5
-
5
-
-
69949096727
-
Mechanism of action of lenalidomide in hematological malignancies
-
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.
-
(2009)
J Hematol Oncol
, vol.2
, pp. 36
-
-
Kotla, V.1
Goel, S.2
Nischal, S.3
Heuck, C.4
Vivek, K.5
Das, B.6
-
6
-
-
54049156803
-
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
-
Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22: 1925-1932.
-
(2008)
Leukemia
, vol.22
, pp. 1925-1932
-
-
Breitkreutz, I.1
Raab, M.S.2
Vallet, S.3
Hideshima, T.4
Raje, N.5
Mitsiades, C.6
-
7
-
-
77950438331
-
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
-
Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010; 107: 5124-5129.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 5124-5129
-
-
Vallet, S.1
Mukherjee, S.2
Vaghela, N.3
Hideshima, T.4
Fulciniti, M.5
Pozzi, S.6
-
8
-
-
0034115270
-
Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma
-
DOI 10.1046/j.1365-2141.2000.01985.x
-
Matsuo Y, Drexler HG, Nishizaki C, Harashima A, Fukuda S, Kozuka T et al. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma. Br J Haematol 2000; 109: 54-63. (Pubitemid 30340579)
-
(2000)
British Journal of Haematology
, vol.109
, Issue.1
, pp. 54-63
-
-
Matsuo, Y.1
Drexler, H.G.2
Nishizaki, C.3
Harashima, A.4
Fukuda, S.5
Kozuka, T.6
Sezaki, T.7
Orita, K.8
-
9
-
-
77951579858
-
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition
-
Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010; 29: 2325-2336.
-
(2010)
Oncogene
, vol.29
, pp. 2325-2336
-
-
Santo, L.1
Vallet, S.2
Hideshima, T.3
Cirstea, D.4
Ikeda, H.5
Pozzi, S.6
-
10
-
-
70349439276
-
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties
-
Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009; 15: 5829-5839.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5829-5839
-
-
Pozzi, S.1
Vallet, S.2
Mukherjee, S.3
Cirstea, D.4
Vaghela, N.5
Santo, L.6
-
11
-
-
38849130851
-
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice
-
DOI 10.1172/JCI33102
-
Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118: 491-504. (Pubitemid 351206540)
-
(2008)
Journal of Clinical Investigation
, vol.118
, Issue.2
, pp. 491-504
-
-
Mukherjee, S.1
Raje, N.2
Schoonmaker, J.A.3
Liu, J.C.4
Hideshima, T.5
Wein, M.N.6
Jones, D.C.7
Vallet, S.8
Bouxsein, M.L.9
Pozzi, S.10
Chhetri, S.11
Seo, Y.D.12
Aronson, J.P.13
Patel, C.14
Fulciniti, M.15
Purton, L.E.16
Glimcher, L.H.17
Lian, J.B.18
Stein, G.19
Anderson, K.C.20
Scadden, D.T.21
more..
-
12
-
-
36348988548
-
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
-
DOI 10.1182/blood-2007-05-093294
-
Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007; 110: 3744-3752. (Pubitemid 350159645)
-
(2007)
Blood
, vol.110
, Issue.10
, pp. 3744-3752
-
-
Vallet, S.1
Raje, N.2
Ishitsuka, K.3
Hideshima, T.4
Podar, K.5
Chhetri, S.6
Pozzi, S.7
Breitkreutz, I.8
Kiziltepe, T.9
Yasui, H.10
Ocio, E.M.11
Shiraishi, N.12
Jin, J.13
Okawa, Y.14
Ikeda, H.15
Mukherjee, S.16
Vaghela, N.17
Cirstea, D.18
Ladetto, M.19
Boccadoro, M.20
Anderson, K.C.21
more..
-
13
-
-
67349099081
-
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
-
Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009; 23: 961-970.
-
(2009)
Leukemia
, vol.23
, pp. 961-970
-
-
Raje, N.1
Hideshima, T.2
Mukherjee, S.3
Raab, M.4
Vallet, S.5
Chhetri, S.6
-
14
-
-
51349137097
-
Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling
-
Samee N, Geoffroy V, Marty C, Schiltz C, Vieux-Rochas M, Levi G et al. Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am J Pathol 2008; 173: 773-780.
-
(2008)
Am J Pathol
, vol.173
, pp. 773-780
-
-
Samee, N.1
Geoffroy, V.2
Marty, C.3
Schiltz, C.4
Vieux-Rochas, M.5
Levi, G.6
-
15
-
-
74949100969
-
Pathogenesis of myeloma bone disease
-
Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem 2010; 109: 283-291.
-
(2010)
J Cell Biochem
, vol.109
, pp. 283-291
-
-
Roodman, G.D.1
-
16
-
-
23744498205
-
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
-
DOI 10.1182/blood-2004-12-4986
-
Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472-2483. (Pubitemid 41510822)
-
(2005)
Blood
, vol.106
, Issue.7
, pp. 2472-2483
-
-
Giuliani, N.1
Colla, S.2
Morandi, F.3
Lazzaretti, M.4
Sala, R.5
Bonomini, S.6
Grano, M.7
Colucci, S.8
Svaldi, M.9
Rizzoli, V.10
-
17
-
-
0035195019
-
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications
-
Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950-1961. (Pubitemid 33115003)
-
(2001)
Leukemia
, vol.15
, Issue.12
, pp. 1950-1961
-
-
Gupta, D.1
Treon, S.P.2
Shima, Y.3
Hideshima, T.4
Podar, K.5
Tai, Y.T.6
Lin, B.7
Lentzsch, S.8
Davies, F.E.9
Chauhan, D.10
Schlossman, R.L.11
Richardson, P.12
Ralph, P.13
Wu, L.14
Payvandi, F.15
Muller, G.16
Stirling, D.I.17
Anderson, K.C.18
-
18
-
-
36349023319
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
DOI 10.1056/NEJMoa070594
-
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132. (Pubitemid 350146107)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.21
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
Prince, H.M.4
Harousseau, J.-L.5
Dmoszynska, A.6
San Miguel, J.7
Hellmann, A.8
Facon, T.9
Foa, R.10
Corso, A.11
Masliak, Z.12
Olesnyckyj, M.13
Yu, Z.14
Patin, J.15
Zeldis, J.B.16
Knight, R.D.17
-
19
-
-
36349010285
-
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
-
DOI 10.1056/NEJMoa070596
-
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142. (Pubitemid 350146108)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.21
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
Wang, M.4
Belch, A.5
Stadtmauer, E.A.6
Siegel, D.7
Borrello, I.8
Rajkumar, S.V.9
Chanan-Khan, A.A.10
Lonial, S.11
Yu, Z.12
Patin, J.13
Olesnyckyj, M.14
Zeldis, J.B.15
Knight, R.D.16
-
20
-
-
0037097595
-
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications
-
DOI 10.1182/blood.V99.12.4525
-
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525-4530. (Pubitemid 34627223)
-
(2002)
Blood
, vol.99
, Issue.12
, pp. 4525-4530
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Poulaki, V.3
Chauhan, D.4
Richardson, P.G.5
Hideshima, T.6
Munshi, N.C.7
Treon, S.P.8
Anderson, K.C.9
-
21
-
-
0035958517
-
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications
-
DOI 10.1038/sj.onc.1204623
-
Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519-4527. (Pubitemid 32772434)
-
(2001)
Oncogene
, vol.20
, Issue.33
, pp. 4519-4527
-
-
Hideshima, T.1
Chauhan, D.2
Schlossman, R.3
Richardson, P.4
Anderson, K.C.5
-
22
-
-
51049087523
-
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation
-
Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 2008; 33: 129-136.
-
(2008)
Int J Oncol
, vol.33
, pp. 129-136
-
-
Munemasa, S.1
Sakai, A.2
Kuroda, Y.3
Okikawa, Y.4
Katayama, Y.5
Asaoku, H.6
-
23
-
-
74849092530
-
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide
-
De Matteo M, Brunetti AE, Maiorano E, Cafforio P, Dammacco F, Silvestris F. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide. Leuk Res 2010; 34: 243-249.
-
(2010)
Leuk Res
, vol.34
, pp. 243-249
-
-
De Matteo, M.1
Brunetti, A.E.2
Maiorano, E.3
Cafforio, P.4
Dammacco, F.5
Silvestris, F.6
-
24
-
-
34548128339
-
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
-
DOI 10.1038/sj.leu.2404843, PII 2404843
-
Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875-1884. (Pubitemid 47299959)
-
(2007)
Leukemia
, vol.21
, Issue.9
, pp. 1875-1884
-
-
Terpos, E.1
Dimopoulos, M.-A.2
Sezer, O.3
-
25
-
-
0033231930
-
Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells
-
DOI 10.1002/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.0.CO;2-T
-
Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y. Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem 1999; 75: 206-214. (Pubitemid 29463489)
-
(1999)
Journal of Cellular Biochemistry
, vol.75
, Issue.2
, pp. 206-214
-
-
Ikenoue, T.1
Jingushi, S.2
Urabe, K.3
Okazaki, K.4
Iwamoto, Y.5
-
26
-
-
34548508972
-
The activin A-follistatin system: Potent regulator of human extracellular matrix mineralization
-
DOI 10.1096/fj.07-8080com
-
Eijken M, Swagemakers S, Koedam M, Steenbergen C, Derkx P, Uitterlinden AG et al. The activin A-follistatin system: potent regulator of human extracellular matrix mineralization. FASEB J 2007; 21: 2949-2960. (Pubitemid 47372761)
-
(2007)
FASEB Journal
, vol.21
, Issue.11
, pp. 2949-2960
-
-
Eijken, M.1
Swagemakers, S.2
Koedam, M.3
Steenbergen, C.4
Derkx, P.5
Uitterlinden, A.G.6
Van Der Spek, P.J.7
Visser, J.A.8
De Jong, F.H.9
Pols, H.A.P.10
Van Leeuwen, J.P.T.M.11
-
27
-
-
0030299826
-
0 exon, functional promoter, and enhancers
-
0 exon, functional promoter, and enhancers. J Biol Chem 1996; 271: 32760-32769.
-
(1996)
J Biol Chem
, vol.271
, pp. 32760-32769
-
-
Tanimoto, K.1
Yoshida, E.2
Mita, S.3
Nibu, Y.4
Murakami, K.5
Fukamizu, A.6
-
28
-
-
0037403844
-
BMP signals regulate Dlx5 during early avian skull development
-
DOI 10.1016/S0012-1606(03)00059-9
-
Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH. BMP signals regulate Dlx5 during early avian skull development. Dev Biol 2003; 257: 177-189. (Pubitemid 36438652)
-
(2003)
Developmental Biology
, vol.257
, Issue.1
, pp. 177-189
-
-
Holleville, N.1
Quilhac, A.2
Bontoux, M.3
Monsoro-Burq, A.-H.4
-
29
-
-
0042891942
-
BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression
-
Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003; 278: 34387-34394.
-
(2003)
J Biol Chem
, vol.278
, pp. 34387-34394
-
-
Lee, M.H.1
Kim, Y.J.2
Kim, H.J.3
Park, H.D.4
Kang, A.R.5
Kyung, H.M.6
-
30
-
-
80051473281
-
Crosstalk between Nodal/activin and MAPK p38 signaling is essential for anterior-posterior axis specification
-
Clements M, Pernaute B, Vella F, Rodriguez TA. Crosstalk between Nodal/activin and MAPK p38 signaling is essential for anterior-posterior axis specification. Curr Biol 2011; 21: 1289-1295.
-
(2011)
Curr Biol
, vol.21
, pp. 1289-1295
-
-
Clements, M.1
Pernaute, B.2
Vella, F.3
Rodriguez, T.A.4
-
31
-
-
77957734208
-
Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss
-
Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010; 12: 586-597.
-
(2010)
Curr Opin Mol Ther
, vol.12
, pp. 586-597
-
-
Raje, N.1
Vallet, S.2
-
32
-
-
77956497430
-
RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss in a mouse model of metastatic breast cancer
-
Mulivor AW, Barbosa D, Kumar R, Pearsall AE, Underwood KW, Ucran JA et al. RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss in a mouse model of metastatic breast cancer. Bone 2008; 44(Supplement 2): S221-S222.
-
(2008)
Bone
, vol.44
, Issue.SUPPL. 2
-
-
Mulivor, A.W.1
Barbosa, D.2
Kumar, R.3
Pearsall, A.E.4
Underwood, K.W.5
Ucran, J.A.6
-
33
-
-
44349141964
-
A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity
-
DOI 10.1073/pnas.0711263105
-
Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 2008; 105: 7082-7087. (Pubitemid 351754533)
-
(2008)
Proceedings of the National Academy of Sciences of the United States of America
, vol.105
, Issue.19
, pp. 7082-7087
-
-
Pearsall, R.S.1
Canalis, E.2
Cornwall-Brady, M.3
Underwood, K.W.4
Haigis, B.5
Ucran, J.6
Kumar, R.7
Pobre, E.8
Grinberg, A.9
Werner, E.D.10
Glatt, V.11
Stadmeyer, L.12
Smith, D.13
Seehra, J.14
Bouxsein, M.L.15
-
34
-
-
0026595714
-
Effect of activin A on globin gene expression in purified human erythroid progenitors
-
Shao L, Frigon Jr. NL, Young AL, Yu AL, Mathews LS, Vaughan J et al. Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood 1992; 79: 773-781.
-
(1992)
Blood
, vol.79
, pp. 773-781
-
-
Shao, L.1
Frigon, Jr.N.L.2
Young, A.L.3
Yu, A.L.4
Mathews, L.S.5
Vaughan, J.6
-
35
-
-
0026565263
-
Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis
-
Shiozaki M, Sakai R, Tabuchi M, Nakamura T, Sugino K, Sugino H et al. Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis. Proc Natl Acad Sci USA 1992; 89: 1553-1556.
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 1553-1556
-
-
Shiozaki, M.1
Sakai, R.2
Tabuchi, M.3
Nakamura, T.4
Sugino, K.5
Sugino, H.6
-
36
-
-
65549147617
-
Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women
-
Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009; 24: 744-752.
-
(2009)
J Bone Miner Res
, vol.24
, pp. 744-752
-
-
Ruckle, J.1
Jacobs, M.2
Kramer, W.3
Pearsall, A.E.4
Kumar, R.5
Underwood, K.W.6
-
37
-
-
33750607347
-
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
-
Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
-
(2006)
Blood
, vol.108
, pp. 3458-3464
-
-
Richardson, P.G.1
Blood, E.2
Mitsiades, C.S.3
Jagannath, S.4
Zeldenrust, S.R.5
Alsina, M.6
-
38
-
-
68249135722
-
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
-
Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114: 772-778.
-
(2009)
Blood
, vol.114
, pp. 772-778
-
-
Richardson, P.1
Jagannath, S.2
Hussein, M.3
Berenson, J.4
Singhal, S.5
Irwin, D.6
-
39
-
-
77956555237
-
ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: Preliminary analysis
-
abstract
-
Abdulkadyrov KM, Salogub GN, Khuazheva NK, Woolf R, Haltom E, Borgstein NG et al. ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis,. Blood 2009; 114: 749 abstract.
-
(2009)
Blood
, vol.114
, pp. 749
-
-
Abdulkadyrov, K.M.1
Salogub, G.N.2
Khuazheva, N.K.3
Woolf, R.4
Haltom, E.5
Borgstein, N.G.6
|